GLP Research Unit – In vivo personalized research

In vivo studies play a key role in evaluating the safety, efficacy and performance of medical devices, new drugs, medicinal products or other substances before they are put on the market. The term “in vivo” refers to experiments conducted in living organisms, such as laboratory animals or humans, as opposed to “in vitro” studies, which take place outside the body.

One of the main tenets of conducting in vivo research in our company is to follow the principles of Good Laboratory Practices (GLP), which guarantee the accuracy, reproducibility and reliability of results. Thanks to GLP, in vivo studies are planned, conducted and documented in a well-defined manner, which enables reliable assessment of the effects of medical devices on living organisms.

Different animal models are used in in vivo studies, depending on the purpose of the study and the specifics of the product. Small animal models, such as mice or rats, are often used for initial toxicity and efficacy studies. Large animal models, such as the domestic pig, are more similar to the human body in terms of anatomy and physiology, allowing for more reliable predictions of medical devices, new drugs, medicinal products or other substances performance in humans.

In vivo studies allow assessment of the effects of medical products on the entire body, including organ systems and biological processes. They can be used to identify potential side effects, assess the bioavailability of active substances and monitor long-term therapeutic effects.

In conclusion, in vivo testing is an indispensable step in the evaluation process of medical devices, new drugs, medicinal products or other substances, providing reliable and comprehensive information on their effects on living organisms. By using small- and large-animal models and adhering to GLP principles, it is possible to better understand the effects of medical devices, new drugs, medicinal products or other substances and ensure their safety and efficacy before access to patients.

The Silesian Park of Medical Technologies Kardio-Med Silesia is certified by Good Laboratory Practice in the biocompatibility (scope 9) for biological evaluation of medical devices for in vitro testing, among others. We also perform in vitro tests without GLP certification confirmation but with the highest quality standards.

Feel free to contact us to match the appropriate testing method to your medical device.

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    I consent to the processing of my personal data by Śląski Park Technologii Medycznych Kardio-Med Silesia Sp. z o.o., 10C M. Curie-Skłodowskiej St., 41-800 Zabrze, KRS:0000396540, NIP:6482761515, Regon:242742607, as Data Controler in order to receive a response. I can withdraw my consent by submitting a statement to: The Data Controler has notified me that this consent does not affect the legality of the processing carried out on the basis of consent before its withdrawal.

    The information clause on the details of the processing is available here.

    Supporting partners: